Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Garralda, E; Schöffski, P; Oberoi, A; Schuler, M; Richly, H; Ascierto, PA; Lin, CC; Alvarez, R; Patel, SP; Xing, Y; Subbiah, V; Lewis, N; Patel, S; Wang-L-akshman, L; Lee, JB; Hassounah, NB; Lee, LH; Roy, M; Banerjee, S; Reynolds, A; Koyama, T; Shimizu, T.

Phase I/Ib study evaluating safety, efficacy, pharmacokinetics and pharmacodynamics of NIZ985 monotherapy and in combination with an anti-PD-1 agent in patients with advanced solid tumors or lymphoma

EUROPEAN JOURNAL OF CANCER. 2026; 244: [doi:10.1016/j.ejca.2026.116899]

Luque, M; Morales-Gallego, M; Sanz-Alvarez, M; Arguiñano, C; Rangel, Y; Ramirez-Merino, N; Qin, MJ; Rovira, A; Albanell, J; Madoz-Gúrpide, J; Rojo, F.

Cancer-associated fibroblast-derived protein S100-A11 influences the response to anti-HER2 therapies in HER2-positive breast cancer

NEOPLASIA. 2026; 78: [doi:10.1016/j.neo.2026.101318]

Serna, G; Obón-Santacana, M; Baraibar, I; Moratalla-Navarro, F; Napoli, S; Ruiz-Pace, F; Mulet, N; Guinó, E; Alonso, L; Boleda, L; Garcia, A; Vidal, J; Iglesias, M; Aguilera, L; Landolfi, S; Montes, AF; Vega, MLL; Cuatrecasas, M; Lopez-Prades, S; Gardeazabal, I; López, CL; Cobo, MLC; González-Flores, E; Lopez-Hidalgo, JL; Alfonso, PG; Ortega, L; Roselló, S; Tarazona, N; Navarro, RC; Bambaren, C; Arregui, D; Fasani, R; Gallego, P; Jimenez, J; Santiago, A; Aguilera, M; Colldeforns, B; Bayó, N; Tabernero, J; Élez, E; Moreno, V; Nuciforo, P.

Intratumoral Fusobacterium species and survival in resectable colorectal cancer: a multicenter cohort study

ESMO Open. 2026; 11(8): [doi:10.1016/j.esmoop.2026.108342]

Bringas, M; Echavarría, I; Polo, C; Jiménez-Alduán, N; Flores, C; Muñoz, A; Ortega, L; Torres, G; Soto-Alsar, J; Calvo, A; Alfonso, PG; Pajares, JA; Suárez-González, J; del Monte-Millán, M; Massarrah, T; de la Peña, FA; Martín, M; Márquez-Rodas, I.

Mainstream and fast-track genetic testing in pancreatic cancer patients and its impact on treatment: our experience in a tertiary hospital in Spain

Familial Cancer. 2026; 25(3): [doi:10.1007/s10689-026-00595-8]

Berciano-Guerrero, M; Pérez-Ruiz, E; Soria, A; Martínez, JM; de Miguel, PA; Muñoz-Couselo, E; Bellido, L; Castro, RL; Espinosa, E; Sanz, LG; Cerezuela-Fuentes, P; Castaño, AG; Crespo, G; Puértolas, T; de la Rosa, CA; Subias, MC; Balea, BC; Rodríguez, AB; Pérez, VN; Lecumberri, MJ; Arroyo, FRG; Tomás, AJC; Mujika, K; Fernández, LA; Guzmán, JCV; Hernández, B; Rodríguez, JF; Manzano, JL; Algarra, SM; Márquez-Rodas, I.

Real-world effectiveness of chemotherapy regimens after immunotherapy in patients with advanced melanoma in Spain: Results from the GEM1801 study

CANCER. 2026; 132(14): [doi:10.1002/cncr.70497]

Alvarez, RMA; Broto, JZM; Trufero, JM; García, AS; Morales, CMV; López, JG; Machín, CM; Gil, A.

Expert opinion document on the management of desmoid tumours in adult patients in Spain

Clinical & Translational Oncology. 2026; : [doi:10.1007/s12094-026-04482-7]

Jaime, JC; de Castro, J; Azkarate, A; Ledo, GG; Calles, A; Marsé, R; Parreira, ASDM; Villamayor, J; Gutiérrez-Sainz, L; Benítez-Fuentes, JD; Elía, DC; Gutiérrez, N; Valles, MA; Sarró, E; López, N.

Real-World Insights into Stage I-III Non-Small Cell Lung Cancer in Spain in the Pre-Immunotherapy Era Using AI Techniques: The IntellyLUNG Study

Life-Basel. 2026; 16(7): [doi:10.3390/life16071119]

Fraile-Lara, L; Andrés, R; Servitja, S; Carrasco, E; Guerrero, A; Bermejo, B; Antón, A; Cruz, J; Alvarez, I; Aguiar, D; Martínez, P; Rodríguez-Lescure, A; Blasco, A; Martín, M; López-Tarruella, S.

Clinical and pathologic insights into early and late breast cancer relapses: a real-world analysis from the El Álamo IV registry

Clinical & Translational Oncology. 2026; : [doi:10.1007/s12094-026-04419-0]

Aguilar, A; Cobo, M; Calles, A; Azkarate, A; Gonzalez-Cao, M; Molina-Vila, MA; Rosell, R.

Phase Ib of repotrectinib plus osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer

LUNG CANCER. 2026; 217: [doi:10.1016/j.lungcan.2026.109461]

Riveiro-Barciela, M; Esteban, P; Vega-Cano, KS; Mateos, B; Miranda, EL; Jara, P; Martin, M; López, SA; Salcedo, M; Forns, X; Garcia-Fructuoso, I; Martinez-Sáez, O; Pinazo-Bandera, J; Garcia-Cortés, M; Ribelles, N; Nanclares, AR; Morchón-Araujo, D; Rodriguez, CA; Lozano, R; Dominguez-Gómez, R; Cejuela, M; Torres-Sempere, J; Ruiz-Cobo, JC; Villagrasa, A; Zamora, E; Buti, M; Bellet, M.

Clinical features and management for CDK4/6 inhibitor-DILI

JHEP Reports. 2026; 8(7): [doi:10.1016/j.jhepr.2026.101873]

Chacón-Ovejero, B; Pacheco-Barcia, V; Palka-Kotlowska, M; Custodio-Cabello, S; Guerra-Hernandez, R; Jimenez-Fonseca, P; Muñoz-Martin, A; Gómez-Cerezo, JF; Cabezón-Gutiérrez, L.

Beyond body surface area: CT-derived body composition as a predictor of chemotherapy toxicity and survival in pancreatic ductal adenocarcinoma: a systematic review

CANCER TREATMENT REVIEWS. 2026; 148: [doi:10.1016/j.ctrv.2026.103174]

Di Grazia, G; Di Lauro, V; Morchón-Araujo, D; Nucera, S; Figuero-Pérez, L; Calleja-Holgado, FJ; Sánchez, DP; Wallbaum, B; Vargas, PR; Palleschi, M; Musolino, A; Cobos, GZ; Paradís, AL; Barroso, G; Cano, OC; Portulas, ED; Caltavituro, A; Buono, G; Gillaranz, YJ; Echavarría, I; López-Tarruella, S; Sirvén, MB; Martínez-Sáez, O; Adamo, B; Mateu, MM; Arpino, G; Bayona, RS; De Laurentiis, M; Rodríguez, CA; Pascual, T; Losada, MV; Schettini, F.

Association between chemotherapy use and prognosis in young patients with stage I-II ER+ /HER2-negative breast cancer according to Prosigna®: An international real-world analysis with propensity-score matching

EUROPEAN JOURNAL OF CANCER. 2026; 242: Nº de citas: 1 [doi:10.1016/j.ejca.2026.116818]

Harris, WP; García-Alfonso, P; Metges, JP; Cubillo-Gracian, A; Zaanan, A; Carlos, LL; Ronzoni, M; Ponz-Sarvise, M; Baakili, A; Kefsi, A; Andrieu, L; Agrawal, M; Wang, WT; Paehler, T; Abbadessa, G; Van Cutsem, E.

Evaluating pegenzileukin (SAR444245/THOR-707) in combination with pembrolizumab or cetuximab in advanced metastatic gastrointestinal cancer: the PEGATHOR phase 2 study

INVESTIGATIONAL NEW DRUGS. 2026; : [doi:10.1007/s10637-026-01622-2]

Fernández-Fernández, I; Castro-Sánchez, E; Rodríguez-Calero, MA; Bujalance-Hoyos, J; Cobo-Sánchez, JL; Parra-García, G; Cubero-Pérez, MA; García-Garrido, JM; Blanco-Mavillard, I.

Variability in Vascular Access Device Use, Dwell Time and Failure: Insights From Routine Nursing Documentation in a Multicentre Cohort Study

JOURNAL OF CLINICAL NURSING. 2026; : [doi:10.1111/jocn.70397]

Dieras V; Curigliano G; Martin M; Lerebours F; Tsurutani J; Savard MF; Jerzak KJ; Hu X; Martins de Aquino Pimentel LC; O'Sullivan CC; Tokunaga E; Okines A; Huang CS; Jacot W; Sohn J; Cronemberger Silva E; Mueller V; Yang S; Granata G; Shen Q; Santarpia L; Hamilton E.

HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer.

JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(17): 1597-1607 Nº de citas: 16 [doi:10.1200/JCO-25-02600]

Torres-Jiménez, J; Fuentes, JDB; Morales, MG; Ozores, PP; Ruiz-Casado, AI; Vieito, M; Serrano-Gómez, C; Esteban-Villarrubia, J; Calvo, A; Garralda, E; Moreno, V; Corbacho, JG; Martin-Liberal, J; Sarrió, RG.

Inequities in enrollment across clinical trial phases and the need for a Spanish perspective

Clinical & Translational Oncology. 2026; : [doi:10.1007/s12094-026-04428-z]

Muñoz-Casares, FC; Gómez-Barbadillo, J; Alvarez-Alvarez, R; Hindi, N; Sebio, A; Lozano-Lominchar, P; Fernández-Hernández, JA; Vasques, H; Muñoz-Muñoz, P; Asencio-Pascual, JM.

Surgical Management and Therapeutic Strategy of Uterine Sarcoma According to Histological Subtype and Staging: Updated Review and Recommendations

Cancers. 2026; 18(12): [doi:10.3390/cancers18121870]

Fakih, M; Gill, S; Sampat, K; Chan, DL; Fisher, G; Cruz-Correa, M; Lenz, HJ; Garcia-Alfonso, P; Forget, F; Lonardi, S; Krauss, J; Chen, E; Gracian, AC; Liu, Y; van Buuren, N; Shao, J; Dong, M; Chen, A; Tejani, M; Hecht, JR.

Phase II randomised study of magrolimab combined with bevacizumab-FOLFIRI in patients with previously treated advanced inoperable metastatic colorectal cancer

ESMO Gastrointestinal Oncology. 2026; 12: [doi:10.1016/j.esmogo.2026.100324]